Boston Scientific deals with debt

No need to sell the farm--or at least not all of it. Embattled medical device maker Boston Scientific made a $1 billion loan payment and restructured some of its other debt, giving itself a breather on a long uphill road back to financial health.

Boston Scientific has a steep climb to make. Last month, Moody's cut its bond rating to "junk." The company's stock is trading at a five-year low. It's carrying billions in debt. And its core business is shaky; stents have come under fire recently for failing to beat cardiac drugs at preventing future heart problems. Now, the company is looking to cut jobs, and possibly sell three of its businesses, which could raise $500 million to $600 million.

- see Boston Scientific's release
- read the report from The Boston Globe

Related Articles:
Tough times for stent market. Report
Stent study surprises. Report
Decline in drug-coated stent use at cardiac centers. Report
Insurers may cut stent payouts. Report

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.